Lilly Korea Plans to Launch Zyprexa IntraMuscular

Published: 2005-03-14 06:57:00

Updated: 2005-03-14 06:57:00

Lilly Korea recently announced that it plans to introduce Zyprexa IntraMuscular (olanzapine for injection) in the domestic market during the first half of this year, giving the healthcare professionals a new option for the rapid control of acute agitation and disturbed behaviors in patients with ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK